Eli Lilly and Company (NYSE:LLY) Trading Down 2.2% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) were down 2.2% during mid-day trading on Friday . The company traded as low as $1,171.20 and last traded at $1,182.2430. 2,106,481 shares were traded during trading, a decline of 32% from the average daily volume of 3,111,201 shares. The stock had previously closed at $1,209.00.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. regulator approved Lilly’s once-daily oral weight-loss pill, Foundayo (orforglipron), giving the company an important commercial foothold in Europe and expanding its obesity-treatment opportunity. Eli Lilly Just Scored Europe’s First Weight Loss Pill Approval
• Positive Sentiment: Foundayo generated $98 million in second-quarter sales following its April launch, providing an early indication that Lilly’s oral GLP-1 franchise could complement Mounjaro and Zepbound. LLY’s Foundayo Posts $98M in Q2 Sales
• Positive Sentiment: Lilly is expanding its obesity pipeline with a new Phase 1 macupatide study in Japan. The trial adds geographic reach and another potential growth driver, although it remains at an early development stage. Lilly Expands Obesity Pipeline With Fresh Macupatide Trial in Japan
• Neutral Sentiment: Analysts continue to view LLY as a fundamental powerhouse nearing a technical buy point, but the stock’s elevated valuation and imperfect chart setup may be limiting new buying. Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains
• Negative Sentiment: Recent insider sales, including a 2,000-share sale by Chief Accounting Officer Donald Zakrowski, may be contributing to caution after Lilly’s substantial earnings-driven advance. Donald Zakrowski Sells 2,000 Shares of Eli Lilly
• Negative Sentiment: Competitive pressure remains a concern as Novo Nordisk argues the obesity market will support multiple differentiated treatments rather than a single dominant winner. That view could temper expectations for Lilly’s market share and long-term pricing power. Novo CEO Says Obesity Market Won’t Be Winner-Take-All

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LLY. Cantor Fitzgerald raised their price target on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Citigroup increased their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Barclays raised their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. Truist Financial lifted their target price on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $1,400.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company Stock Down 2.2%

The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market cap of $1.11 trillion, a PE ratio of 39.67, a P/E/G ratio of 1.44 and a beta of 0.51. The stock has a 50-day moving average of $1,169.84 and a 200-day moving average of $1,051.85.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts predict that Eli Lilly and Company will post 36.33 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 23.22%.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Large investors have recently added to or reduced their stakes in the company. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $30,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares in the last quarter. New England Capital Financial Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares during the last quarter. Finally, Maseco LLP lifted its holdings in shares of Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after acquiring an additional 28 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.